Loading...

Nanobiotix S.A.

0QAV.L•LSE
Healthcare
Medical - Pharmaceuticals
£4.42
£-0.22(-4.74%)

Nanobiotix S.A. (0QAV.L) Stock Overview

Explore Nanobiotix S.A.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B+

Score: 70.6/100

Key Financials

Market Cap223.5M
P/E Ratio-6.57
EPS (TTM)$-1.35
ROE2.83%
Fundamental Analysis

AI Price Forecasts

1 Week$4.06
1 Month$3.28
3 Months$3.20
1 Year Target$2.35

0QAV.L Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Nanobiotix S.A. (0QAV.L) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 65.74, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $2.35.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -6.57 and a market capitalization of 223.5M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Technical Indicators

65.74RSI (14)
0.20MACD
37.44ADX
Revenue Growth
-138.62%
↓ 138.62%
Profit Growth
£-0.71
↓ 71.62%
EPS Growth
£-0.71
↓ 33.33%
Operating Margin
-53.34%
↓ 155.39%
ROE
283.43%
↓ 71.62%
Dividend Yield
0.00%
Analyst Recommendations data is not available for 0QAV.LAnalyst Recommendations details for 0QAV.L are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.

CEO

Laurent Levy

Employees

108

Headquarters

60 rue de Wattignies, Paris

Founded

2014

Frequently Asked Questions

;